3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
4
Prostatic Neoplasms, Castration-Resistant
1
Prostate Cancer Non-Metastatic
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer
1
Breast Neoplasms
1
Biochemically Recurrent Prostate Cancer
1
Interventions
Cetuximab
4
Radiosurgery
3
Nivolumab
3
Ipilimumab
3
pembrolizumab
2
Vorinostat
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Dasatinib
2
Cisplatin
2
CTLA-4 Antigen
2
Bevacizumab
2
temsirolimus
1
ispinesib
1
eribulin
1
dehydroftorafur
1
apalutamide
1
amivantamab
1
alectinib
1
Specimen Handling
1
Sorafenib
1
Sirolimus
1
Platinum
1
Pilocarpine
1
Pemetrexed
1
Oral Hygiene
1
NVP-BKM120
1
Moxibustion
1
MK 2206
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Salivary Gland Neoplasms
×
darolutamide
×
Clear all
No trials found.